DK0980263T3 - Kombinationsprodukt, som kombinerer en nukleinsyre med en substans, der opløser den ekstracellulære matrix, til genterapi - Google Patents

Kombinationsprodukt, som kombinerer en nukleinsyre med en substans, der opløser den ekstracellulære matrix, til genterapi

Info

Publication number
DK0980263T3
DK0980263T3 DK98928391T DK98928391T DK0980263T3 DK 0980263 T3 DK0980263 T3 DK 0980263T3 DK 98928391 T DK98928391 T DK 98928391T DK 98928391 T DK98928391 T DK 98928391T DK 0980263 T3 DK0980263 T3 DK 0980263T3
Authority
DK
Denmark
Prior art keywords
nucleic acid
extracellular matrix
gene therapy
dissolves
substance
Prior art date
Application number
DK98928391T
Other languages
English (en)
Inventor
Serge Braun
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of DK0980263T3 publication Critical patent/DK0980263T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK98928391T 1997-05-29 1998-05-29 Kombinationsprodukt, som kombinerer en nukleinsyre med en substans, der opløser den ekstracellulære matrix, til genterapi DK0980263T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9706600A FR2763958A1 (fr) 1997-05-29 1997-05-29 Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
PCT/FR1998/001084 WO1998053853A1 (fr) 1997-05-29 1998-05-29 Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique

Publications (1)

Publication Number Publication Date
DK0980263T3 true DK0980263T3 (da) 2003-02-03

Family

ID=9507375

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98928391T DK0980263T3 (da) 1997-05-29 1998-05-29 Kombinationsprodukt, som kombinerer en nukleinsyre med en substans, der opløser den ekstracellulære matrix, til genterapi

Country Status (12)

Country Link
US (1) US6258791B1 (da)
EP (1) EP0980263B1 (da)
JP (1) JP2002500662A (da)
AT (1) ATE224736T1 (da)
AU (1) AU752146B2 (da)
CA (1) CA2291590A1 (da)
DE (1) DE69808274T2 (da)
DK (1) DK0980263T3 (da)
ES (1) ES2181234T3 (da)
FR (1) FR2763958A1 (da)
PT (1) PT980263E (da)
WO (1) WO1998053853A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0998945A1 (en) * 1998-09-30 2000-05-10 Transgene S.A. Use of magnesium (Mg2+) for the enhancement of gene delivery in gene therapy
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
WO2000034500A2 (en) * 1998-12-04 2000-06-15 Genzyme Corporation Methods for increasing the efficiency of gene transfer
ATE245452T1 (de) * 1998-12-23 2003-08-15 Esparma Gmbh Hyaluronatlyase als penetrationsförderer in topischen mitteln
IL152420A0 (en) * 2001-02-23 2003-05-29 Novartis Ag Novel oncolytic adenoviral vectors
JP2005524389A (ja) * 2001-11-26 2005-08-18 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 宿主組織内への核酸分子の電気的遺伝子導入の増強
EP1480656A4 (en) * 2002-02-15 2007-07-18 Res Dev Foundation ADENOVIRAL TRANDUCTION INDUCED BY HYALURONIC ACID
DE10211457A1 (de) * 2002-03-12 2003-09-25 Knoell Hans Forschung Ev Verwendung von Hyaluronatlyase zur Behandlung von Myokardinfarkten
WO2003100031A2 (en) * 2002-05-20 2003-12-04 Board Of Regents, The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
WO2004098534A2 (en) * 2003-02-24 2004-11-18 Therion Biologics Corporation Methods for delivering angiogenic modulators using pox viruses
NZ542873A (en) 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
US20050014714A1 (en) * 2003-06-04 2005-01-20 The Johns Hopkins University Gene delivery to organs
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
US7888201B2 (en) * 2003-11-04 2011-02-15 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor-on-insulator SRAM configured using partially-depleted and fully-depleted transistors
US7572613B2 (en) * 2004-06-25 2009-08-11 Klein Jeffrey A Drug delivery system for accelerated subcutaneous absorption
JP2007175021A (ja) * 2005-12-28 2007-07-12 Sysmex Corp 大腸がんのリンパ節転移マーカー
CA2678038C (en) * 2007-02-15 2016-10-11 Allergan, Inc. Use of botulinum toxin and enzymes for treating bladder or prostate disorders, or hyperhydrosis
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
WO2010138918A1 (en) * 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
JP6194248B2 (ja) 2010-10-28 2017-09-06 パシラ ファーマシューティカルズ インコーポレーテッド 非ステロイド性抗炎症薬の徐放性処方物
EP3587455A1 (en) 2012-10-23 2020-01-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
US11826423B2 (en) 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
EP3541815A4 (en) 2016-11-18 2020-07-15 Pacira Pharmaceuticals, Inc. ZINC MELXICAM COMPLEX MICROPARTICLE MULTIVESICULAR LIPOSOME FORMULATIONS AND METHODS OF MAKING THE SAME
IL270024B2 (en) 2017-04-22 2025-04-01 Immunomic Therapeutics Inc LAMP structures and their use in vaccination
KR20200016224A (ko) 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
EP3793595A1 (en) 2018-05-15 2021-03-24 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
WO2020061528A1 (en) 2018-09-21 2020-03-26 University Of Connecticut Compositions and methods to restore paternal ube3a gene expression in human angelman syndrome
JP2022551732A (ja) 2019-10-18 2022-12-13 イミュノミック セラピューティックス， インコーポレイテッド がん抗原を含む改良ｌａｍｐ構築物
US12564646B2 (en) * 2021-06-16 2026-03-03 BioViva USA, Inc. Treatment of age-related cognitive decline using genetically modified viral vectors
EP4508071A1 (en) 2022-04-10 2025-02-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012329A2 (en) * 1990-02-12 1991-08-22 Board Of Regents, The University Of Texas System Satellite cell proliferation in adult skeletal muscle
HRP930935A2 (en) * 1992-06-11 1994-12-31 Astra Ab New dna sequences
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
FR2732895B1 (fr) 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US6177410B1 (en) 1997-12-05 2001-01-23 Vanderbilt University Therapeutic methods for prostate cancer

Also Published As

Publication number Publication date
CA2291590A1 (fr) 1998-12-03
EP0980263B1 (fr) 2002-09-25
FR2763958A1 (fr) 1998-12-04
US6258791B1 (en) 2001-07-10
DE69808274D1 (de) 2002-10-31
ES2181234T3 (es) 2003-02-16
AU752146B2 (en) 2002-09-05
WO1998053853A1 (fr) 1998-12-03
JP2002500662A (ja) 2002-01-08
AU8023898A (en) 1998-12-30
ATE224736T1 (de) 2002-10-15
EP0980263A1 (fr) 2000-02-23
PT980263E (pt) 2003-02-28
DE69808274T2 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
DK0980263T3 (da) Kombinationsprodukt, som kombinerer en nukleinsyre med en substans, der opløser den ekstracellulære matrix, til genterapi
ATE228507T1 (de) Substituierte 6-phenylphenanthridine
NO20022095L (no) Heterocyklisk substituerte pyrazoloner
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
TR200103186T2 (tr) MEK enzimlerinin inhibitörleri olarak kinolin türevleri
TR200000927T2 (tr) Prostaglandin agonistleri ve kemik bozukluklarının tedavisi
ATE429210T1 (de) Orale flüssige zusammensetzungen
BR0010220A (pt) Compostos de pirimidinona
BRPI0515012A (pt) substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
NO20043257L (no) Innkapslede bindingsproteiner som biosensorer
NO20051102L (no) Sulfonylamino-eddiksyre-derivater
NO20034230D0 (no) 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister
ATE396993T1 (de) Tetrahydropyranyl-cyclopentyl- tetrahydropyridopyridin-modulatoren der chemokin- rezeptor-aktivität
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
TR200001203T2 (tr) Yeni birleşik maddeler
BR9713338A (pt) Benzonaftiridinas como terapêuticos brÈnquicos.
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
ATE423562T1 (de) Alpha-ketoamidhaltige multikatalytische protease inhibitoren
DE50204688D1 (de) N-alkylaziridinoprepolymere als dentalmasse
DK0782567T3 (da) Isothiourinstofderivater og fremgangsmåder til deres fremstilling
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
BR0303912A (pt) Composição para o condicionamento, composição para o condicionamento durável, método para o condicionamento, método para o condicionamento durável, método para o cuidado ou tratamento e kit para o cuidado, tratamento, condicionamento ou condicionamento durável